Heart failure (HF) is a complex syndrome that is increasing in prevalence on a worldwide
basis and carries a high morbidity and mortality resulting in a huge economic burden.
Although HF is initially driven by primary cardiac dysfunction, the syndrome culminates
into a multisystem process involving the central nervous system, lungs, kidneys, and
skeletal muscles. Targeting the involvement of noncardiac pathways remains an important
approach to minimize the progression of HF and to improve clinical outcomes. As highlighted
in the July 2015 issue of the Canadian Journal of Cardiology, sleep disordered breathing is strongly associated with HF, and treatment of central
sleep apnea (CSA) and obstructive sleep apnea plays an important role in the management
of these patients.
1
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Heart failure and sleep apnea.Can J Cardiol. 2015; 31: 898-908
- Adaptive servoventilation for treatment of sleep-disordered breathing in heart failure: a systematic review and meta-analysis.Chest. 2012; 142: 1211-1221
Specific ResMed ventilators with adaptive ServoVentilation (ASV) - increased risk of cardiovascular death in patients who have a specific heart condition. Available at: https://www.gov.uk/drug-device-alerts/specific-resmed-ventilators-with-adaptive-servoventilation-asv-increased-risk-of-cardiovascular-death-in-patients-who-have-a-specific-heart-condition. Accessed June 12, 2015.
- Cheyne-stokes respiration: Friend or foe?.Thorax. 2012; 67: 357-360
- Continuous positive airway pressure for central sleep apnea and heart failure.N Engl J Med. 2005; 353: 2025-2033
Article info
Publication history
Accepted:
July 22,
2015
Received:
July 22,
2015
Footnotes
See page 1203 for disclosure information.
Identification
Copyright
© 2015 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Reply to Letter From Floras et al.—Central Sleep Apnea: Risk Factor or Pathogenic Process in Patients With Heart FailureCanadian Journal of CardiologyVol. 32Issue 3
- PreviewWe thank Floras et al.1 for their interest in our News and Commentary on the use of adaptive servo-ventilation (ASV) therapy in symptomatic patients with heart failure and reduced ejection fraction.2 As clearly delineated in our News and Commentary, the safety advisory was issued based on the findings of increased mortality in patients receiving ASV in the Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure (SERVE-HF) trial. The actual results of the trial were presented at the 2015 European Society of Cardiology Congress and recently published in the New England Journal of Medicine.
- Full-Text
- Preview
- Adaptive Servo Ventilation for Central Sleep Apnea: More Data, PleaseCanadian Journal of CardiologyVol. 32Issue 3
- PreviewThe SERVE-HF trial (Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure) commentary by Yogasundaram and Oudit contains a factual error and several misconceptions that could discourage others from initiating or completing other trials such as the ADVENT-HF trial (A Multi-Centre Randomized Study to Assess the Effects of Adaptive Servo Ventilation on Survival and Frequency of Cardiovascular Hospital Admissions in Patients with Heart Failure and Sleep Apnea) of adaptive servo-ventilation (ASV) for the treatment of central sleep apnea (CSA) and obstructive sleep apnea (OSA) in heart failure (HF) that involve different devices.
- Full-Text
- Preview
